Nimotuzumab binding is heavily dependent on cell receptor density, which means the mAb binds high EGFR-expressing tumor cells with increased avidity, whilst at the same time sparing low EGFR-expressing normal cells, hence avoiding unnecessary adverse effects, such as skin toxicity, which is frequently seen with other EGFR mAbs, all without compromising on efficacy [6]. This evidence concerns the gene EGFR and neoplasm.